Item 2.02 Results of Operations and Financial Condition

On January 11, 2022, the Company posted investor presentation materials that the Company will be presenting at the 40th Annual J.P. Morgan Healthcare Conference on the investor relations section of the Company's website. In these materials, the Company reaffirmed previously issued Total Revenue guidance and stated that it anticipates meeting or exceeding previously issued Adjusted EBITDA guidance for the year ended December 31, 2021. A copy of the investor presentation materials is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure

The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



    Exhibit No.                                           Description
  99.1                      Investor Presentation
104                       The cover page from this Current Report on Form 8-K, formatted as Inline
                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses